Prostate Cancer clinical trials
Showing 701–735 of 735 active trials. Describe your situation to see which ones you may be eligible for.
- Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
- A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
- [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application
- Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer
- Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
- Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
- A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer
- A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
- Periprostatic Neurolysis in Prostate Cancer
- AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft
- Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
- Pivotal Study of Voro Urologic Scaffold
- Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
- Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
- Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
- Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion
- Phase II Trial to Investigate the Safety and Efficacy of Four Dosing Regimens of OTL78 Injection
- WATER IV Prostate Cancer
- A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
- Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
- Multicenter Trial of ESK981 in Patients With Select Solid Tumors
- A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
- A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
- Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
- 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
- Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
- PSMA PET Scan and mpMRI for Prostate Cancer Detection
- Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
- PRISM: Patient Experiences With PET Imaging in Prostate Cancer
- Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)
- Exercise Therapy and Radiation Therapy (EXERT) for Metastatic Prostate Cancer
- Increasing Access to Definitive Treatment for Prostate Cancer
- Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers
- Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
- DISCO: A Patient Intervention to Reduce the Financial Burden of Cancer
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.